Organic Active Ingredients TRIZ Cases

Oral TUDCA offers a well-tolerated way to slow ALS progression, delay functional decline, and improve quality of life alongside standard care.

Using R-152a propellant with low water and oxygen content stabilizes formoterol-budesonide MDI formulations at ambient temperature.

Distinct ALK inhibitor crystal forms use controlled crystallization and XRPD fingerprints to improve solubility, stability, and bioavailability.

A matrix patch uses lauryl lactate, long-chain fatty alcohols, and micronized risperidone to sustain 14-day delivery with less irritation.

By inhibiting Myosin II, pyridazinone compounds help limit muscle degeneration, inflammation, and fibrosis in DMD and BMD.

Flavagline derivatives target prohibitin to disrupt KRAS-CRAF binding, enabling selective KRAS4A/4B inhibition while sparing HRAS and NRAS.

Heating fatty acids with amino acids at 165°C or higher enables direct amidation with high conversion and lower product color, avoiding acid chlorides.

Amphiphilic self-assembled carriers protect peptide drugs from GI degradation while improving solubility and mucosal absorption.

Micronized actives in a water-soluble polymer film enable uniform dosing and precise dissolution profiles for consistent oral drug delivery.

Sequence-specific oligomeric agents lower PCDH19 RNA and protein to help reduce seizures and cognitive impairment in PCDH19-related disorders.

Quaternary ammonium linkers improve FAP inhibitor solubility, metabolic stability, and tissue penetration for better in vivo targeting.

WRG-28 and atovaquone are combined to inhibit CRAC and DDR2 activation, reducing fibrosis, cytokine storms, and metastasis.

Targeting PIP2 trafficking and GsdmD cleavage offers a way to reduce PFIC1 inflammation and hepatocyte damage linked to altered ATP8B1 function.

A preloaded balloon coating delivers therapeutic agents directly to non-vascular strictures, helping reduce recurrence and repeat procedures.

Defined aprocitentan sodium crystal forms improve stability, reduce hygroscopicity, and support reproducible pharmaceutical manufacturing.

Specific heterocyclic scaffolds block PD-L1 and PD-1 binding, expanding treatment options for cancer and other immune-related conditions.

Timed and enteric linkers plus polymer release coatings improve gastric residence control and reduce premature GI passage.

Targeting FOXM1 with a Ser25 mutant peptide or shRNA suppresses tumor growth, invasion, metastasis, and macrophage polarization.

Combining TTFields with IGF1R, JNK, RPS6, or ERK inhibitors helps overcome cancer cell resistance and increase apoptosis.

Combining ibudilast and bumetanide produces measurable EEG changes in ASD by reducing gamma waves and increasing alpha waves.

Modified nucleosides such as MOE improve antisense stability in plasma while strengthening TGF-β2 mRNA inhibition and cancer cell killing.

A quinazolinone BRAF inhibitor with brain penetration and pH-modified tablet delivery addresses efficacy and safety limits in melanoma brain metastases.

Non-coding RNA scaffolds package artificial microRNA hairpins into expression vectors, restoring microRNA function and regulating cancer pathways.

Chemically binding active agents to carbohydrates improves EV loading and intracellular delivery while avoiding membrane damage and aggregation.

Targeting OBSCN-AS1 with CRISPR activation restores OBSCN expression through chromatin remodeling to suppress breast cancer metastasis.

TLR7/TLR8 activation can worsen autoimmune disease, while Formula I compounds selectively inhibit these receptors to support treatment.

Controlled cleavage, cyclization, coupling, and purification raise omapatrilat yield while keeping optical purity high and impurities below 3%.

A Bf 844 compound approach broadens cancer treatment to BRCA-mutated and other hard-to-treat cancers while enhancing existing therapies.

Salt formation and controlled solid forms replace foam isolation and chromatography, cutting residual solvents while supporting stable BTK inhibitor scale-up.

Selective JAK1 inhibition targets IL-31-driven prurigo nodularis to reduce itch and nodules while avoiding broad immunosuppressant toxicity.

T790M EGFR mutations can resist existing therapies; combining plinabulin with osimertinib inhibits cancer growth and induces apoptosis.

Selective quinoline derivatives inhibit Factor XI activation to prevent thrombosis while improving potency and pharmacokinetic balance.

A phase-separated capsaicin emulsion raises drug loading and skin delivery while reducing burning sting pain and pretreatment needs.

A protein-coated grease core with a heat-cured colloid wall protects bioactive substances during sterilization, stirring, and acid exposure.

A CD33/CLL1 bispecific antibody linked to NK cells improves leukemia targeting and killing for relapsed or refractory AML.

Controlled enzymatic branching creates a high-molecular-weight glucan that digests slowly while retaining high digestibility.

A two-pot route combines key reaction and isolation steps to raise diazaspiro undecanone yield while avoiding hazardous reagents and cryogenic cooling.

Allosteric CRFR1 antagonists improve receptor selectivity and safety while reducing p-Tau levels and supporting cognition in AD models.

Separate tablet layers give metformin sustained release and enavogliflozin immediate release, improving uniformity and glucose control.

Oral apremilast dosage forms use controlled release and dose scheduling to support once-daily treatment with fewer gastrointestinal adverse effects.

Blocking nuclear export with inhibitors such as Selinexor helps oncolytic viruses replicate in nonpermissive tumor cells and kill cancer cells.

An antibody-drug conjugate targets BDCA2-positive cells with glucocorticoids, limiting non-targeted toxicity while suppressing inflammation.

Specific 3' hydrophobic substituents improve THRβ selectivity, boosting lipid metabolism while limiting THRα-linked side effects.

Hydroxypropyl cellulose keeps rotigotine dissolved in silicone adhesive, helping prevent crystals while supporting stable transdermal delivery.

Novel cilostazol-derived compounds cross the blood-brain barrier to curb glioblastoma proliferation and slow tumor growth.

An alginate oral film delivers sumatriptan non-invasively while achieving faster, more consistent plasma levels than tablets or nasal sprays.

Specific Formula (I) compounds selectively inhibit TIPARP while minimizing PARP1 and PARP2 inhibition to reduce cytokine-related side effects.

A hydrophilic polymer inner layer and amphiphilic lipid shell limit transit drug loss, prevent burst release, and improve bioavailability.

Dual JAK1/JAK2 and BET inhibition improves myeloproliferative neoplasm control by suppressing inflammatory signaling beyond single-agent therapy.

An isolated Torilidis Fructus compound reduces cancer-cell viability while minimally affecting normal cells across multiple cancer types.

WRN helicase and ATPase inhibition offers a complementary treatment path for MSI-H/dMMR cancers facing checkpoint inhibitor resistance.

Cyclodextrin inclusion complexes improve ticagrelor solubility and protect aqueous solutions from light, heat, and oxygen degradation.

Optimized gRNAs, GFP reporters, and lipid TCVs support more sensitive, specific CRISPR editing detection across tissues.

Stable Forms B and C help limit cabotegravir sodium phase transitions.

Systematic benzimidazole substitutions target TRPC6 activity for therapeutic use in nephrotic syndrome and related diseases.

This case combines AZD5305 with darolutamide to address reduced PARP inhibitor exposure and extend prostate cancer control.

A selective oral small molecule inhibits CSF1R, depletes macrophages, and reduces TGCT burden without antibody-linked CSF1 accumulation.

Compounds trigger iron-dependent ferroptosis and reactive oxygen species to address cancers resistant to chemotherapy or radiation.

A non-cellular root canal filler promotes pulp, dentin, and periapical regeneration without stem cell transplantation.

Triazole derivatives target inflammation and collagen buildup in liver fibrosis.

This case combines enzyme-treated, fermented ginseng extracts with steroids to address limited antiviral coverage and immune suppression.

This case uses 15-PGDH inhibitors to preserve PGE2 activity, increase muscle cell proliferation, and promote regeneration.

Pyrimidine-based tricyclic compounds directly stimulate sGC to enhance cGMP signaling for vascular relaxation and anti-fibrotic effects.

This case examines flexible-chain aminothiols that target ROS and DNA damage while reducing apoptosis in transplant and infarct models.

A 1,1-difluoroethane suspension stabilizes umeclidinium and vilanterol for consistent metered-dose inhaler delivery.

A CTPS1-selective compound targets proliferating immune cells while limiting toxicity.

This case uses PDE1 inhibition to regulate macrophage polarization, reduce cytokine expression, and limit inflammatory tissue damage.

17β-Estradiol loosens epithelium so cells integrate without tissue destruction.

This case combines enzymes and microbicidal molecules to break down implant biofilms and treat infections without tissue damage.

Hydrogen sulphate salt and carrier matrices improve solubility, stability, and bioavailability.

This case uses oxatricyclo carboxamide derivatives to induce chondrogenesis and address cartilage loss without complex surgery.

This case uses ambroxol as a pharmacological chaperone to improve NAGLU activity and lysosomal fusion in MPS III.

This case examines R-5-MAPB and S-6-MAPB compositions that rapidly modulate serotonin and dopamine for mental disorders.

This case uses high-affinity TCR alpha and beta constructs to recognize MYD88 L265P via HLA-B*07:02 and limit off-target toxicity.

Substituted heterocyclic compounds target the SHP2 regulatory interface to modulate activity across SHP2-related diseases.

A base converts amphetamine carbamates to carbonate ions for ion chromatography, supporting accurate testing of transdermal drug matrices.

This composition combines oil palm phenolics with milling-derived fiber to reduce colon DNA damage and strengthen mucus protection.

Optimized G1T38 exposure and dosing parameters support continuous cancer therapy with less neutropenia and gastrointestinal complications.

Small-molecule GLP-1R agonists replace peptide injections with an oral route while supporting glycemic control and weight reduction.

This case uses a circular thrombin-binding aptamer to extend serum stability and support biocompatible thrombin inhibition.

This case uses GSPT1, IKZF1, ATF4, and related biomarkers to monitor pharmacodynamic activity and predict therapy response earlier.

Structural substituents and Suzuki synthesis support benzimidazole treatment aimed at preventing heart failure progression.

Macrocyclic TRK inhibitors target resistant mutations with improved brain penetration.

This case uses dry granulation and excipient ratios to produce high-loading tablets with smaller size and improved manufacturability.

This case uses a specific L-nucleic acid sequence to inhibit CXCL8 chemotaxis while limiting cross-reactivity with related chemokines.

This case uses an eyeshadow composition and permeation enhancers to stimulate Müller's muscle for eyelid separation without surgery.

This case pairs MOR00208 with venetoclax to target CD19 recognition and BCL-2 survival signaling in relapsed B-cell cancers.

This case uses sEH inhibitors to raise epoxy-fatty acids and reduce cognitive and social deficits after maternal immune activation.

This case combines hydrated azithromycin with triacetin, triglycerides, and excipients for effective single-injection feline treatment.

Triple-layer capsules release indigo in the large intestine to limit side effects.

This case uses tomatidine, rapamycin, xylitol, and probiotics to modulate gut bacteria, support bone health, and limit drug side effects.

This case combines peptide recognition with metal-binding groups to improve metalloenzyme inhibition efficacy and specificity.

Targeted PMO delivery enables DMD exon 44 skipping in muscle cells.

This case uses immunoassays and nucleic acid assays to detect repeat proteins and transcripts for earlier ALS and FTD identification.

The case uses oral or intravenous ATP and adenosine supplementation to support survival and potentially avoid mechanical ventilation.

This case uses substituted pyrrolopyrimidine compounds to selectively inhibit CDK 4/6, targeting CSCs and reducing resistance.

DMA and NMP keep lipophilic protides soluble and stable for intravenous delivery.

This case uses nanoparticle size and surface charge to improve tissue targeting, matrix penetration, and cargo retention.

Magnetic nanostructures guide biomolecular cargo into cells with low toxicity.

The case combines β-carboline and pyrazole units, using staged synthesis and chromatography to produce an HGC-27 inhibitor.

Amorphous ospemifene solid dispersions with hydrophilic carriers overcome poor water solubility to improve bioavailability.

Specific phosphate compounds inhibit butyrylcholinesterase activity, reducing beta-amyloid plaque formation while sparing peripheral tissues.

Combining angiotensin II receptor blockers with vaccines blocks monocyte recruitment to lymph nodes, suppressing immunosuppression and enhancing tumor immunity.

Ligand binding removes prion contaminants from albumin nanoparticles, mitigating disease transmission risks in blood-derived products.

Blocking KLRB1-CLEC2D interactions restores natural killer cell cytotoxicity against glioblastoma tumors.

Injecting cross-linked hyaluronic acid gel creates a space filler that maintains drainage pathways during glaucoma surgery.

Enterically-coated dimethyl fumarate particles enable controlled drug release profiles suitable for simplified once-a-day dosing regimens.

Combining AKR1C3-activated alkylating agents with CDK or ATR inhibitors blocks DNA repair checkpoints, overcoming limited tumor inhibition efficacy.

Tailoring tradipitant dosage to specific genotypes and high IgE levels resolves inadequate relief in severe atopic dermatitis cases.

Bifunctional compounds link TRIM24 inhibitors to E3 ligase ligands for targeted protein degradation.

P62 polypeptides resolve inadequate immune stimulation by activating dendritic cells to inhibit tumor growth and reduce metastasis.

Crystal form D of pyrazine-2(1H)-ketone exhibits selective inhibitory activity against FGFR2 and FGFR3 receptors.

Excluding glutamine and glucose from amino acid formulations prevents paracellular permeability spikes while alleviating intestinal inflammation symptoms.

Nor-binaltorphimine eliminates addiction risk by blocking kappa opioid receptors, providing effective ADHD symptom reduction without abuse potential.

C3aR antagonists modulate blood cerebrospinal fluid barrier permeability to inhibit leptomeningeal metastasis.

An injectable depot formulation uses a biocompatible polymer and organic solvent to form a viscous gel that incorporates small molecule drugs.

Surrogate biomarkers resolve measurement feasibility issues caused by adenosine short half-life.

Pulsed electromagnetic field stimulation drives A2a receptor translocation to retinal cell membranes.

Crystalline methanesulfonic acid salt form of a triazolopyridine benzamide resolves stability and predictability trade-offs in kinase inhibitor development.

Modified antisense oligonucleotides inhibit IRF4 expression, resolving the undruggable target bottleneck in hematological malignancies.

Transdermal tandospirone patches stabilize plasma levels, preventing rebound dyskinesia and enabling higher levodopa dosages without worsening symptoms.

Sub-immunosuppressive doses of calcineurin inhibitors lower APOE concentration to reduce amyloid accumulation without causing immunosuppression.

3-Aza-bicyclohexane derivatives act as SSTR4 agonists, resolving the trade-off between metabolic stability and receptor selectivity.

Nested microemulsion phases extend pregabalin duration of action to lower intraocular pressure and protect retinal ganglion cells.

Fecal bacterial gene analysis improves detection sensitivity for precancerous lesions, addressing low accuracy in standard immunochemical tests.

Diphosphate phosphoramidate salts replace ester groups with carboxylic acids to improve solubility while maintaining anticancer potency.

Novel bisaminoquinoline compounds inhibit autophagy through dimeric structures.

Cyclophosphamide liquid formulations achieve stability by reducing moisture content below 2.0% to prevent degradation in aqueous solutions.

Co-administering these inhibitors overcomes drug resistance by targeting distinct metabolic pathways for synergistic anti-cancer efficacy.

A multi-lamellar emulsion structure mimics stratum corneum lipids to enhance drug partitioning.

Fluorine substitution on benzilic acid esters raises urethral baseline pressure to treat stress urinary incontinence without duloxetine side effects.

Optimized amphiphilic carbohydrate polymers balance antiviral efficacy and cytotoxicity through controlled quaternary ammonium group distribution.

Formula I heterocyclic compounds modulate STING signaling to activate immune responses against cancer and infectious diseases.

Direct compression of solifenacin with an antioxidant and binder prevents wet granulation degradation, ensuring content uniformity.

Modified indole-pyrazole compounds overcome resistance to diverse FGFR mutations in lung and gastric cancers.

Chlorophenyl-substituted imidazo[1,2-a]pyridine compounds resolve the contradiction between enzyme inhibition potency and pharmacokinetic half-life.

A Pim1 kinase inhibitor induces Runx3 expression to limit effector T cell expansion and modulate cytokine production.

Adjusting solids concentration and caffeine ratios in porous adsorbents increases treatable material volume while maintaining high caffeine removal efficiency.

Cyclodextrin inclusion complexes with Tecovirimat and meglumine resolve poor water solubility to enable stable injection.

Gut-restricted GPR119 agonists minimize systemic side effects by limiting plasma exposure while maintaining therapeutic activity in the gut.

Pridopidine treats Rett syndrome by delaying symptom onset and improving gait through neuroprotective pathways.

Core-shell nanoparticles inhibit restenosis and promote re-endothelialization by shielding endothelium from indiscriminative drug toxicity.

Segmented triazole inhibitors target specific DAGL isoforms to resolve the lack of effective modulators for neurodegenerative disease treatment.

Reduced dosing frequency of an IL-13 binding protein treats atopic dermatitis while improving patient compliance and tolerability.

Novel acylaminocycloalkyl compounds selectively bind dopamine D3 receptors.

Formula I compounds inhibit c-ABL while maintaining low P-gp efflux and high solubility to treat neurodegenerative diseases and cancers.

Inhalable 4-membered heterocyclic amide compounds inhibit JAK enzymes in lung tissue, reducing systemic side effects.